Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Quoin Pharmaceuticals, Ltd. Sponsored ADR (QNRX) had Return on Tangible Equity of -124.09% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-15.80M |
|
-- |
|
-- |
|
$16.29M |
|
$-16.29M |
|
$0.49M |
|
$-15.80M |
|
$-15.80M |
|
$-15.80M |
|
$-15.80M |
|
$-15.80M |
|
$-15.80M |
|
$-16.29M |
|
$-16.19M |
|
1.07M |
|
1.07M |
|
$-14.80 |
|
$-14.80 |
|
| Balance Sheet Financials | |
$20.01M |
|
-- |
|
$0.38M |
|
$20.39M |
|
$5.55M |
|
-- |
|
$1.72M |
|
$7.27M |
|
$13.12M |
|
$12.74M |
|
$13.12M |
|
0.26M |
|
| Cash Flow Statement Financials | |
$-13.54M |
|
$-4.28M |
|
$18.01M |
|
$3.62M |
|
$3.82M |
|
$0.19M |
|
$1.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.61 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-13.54M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-120.46% |
|
|
Return on Tangible Equity |
-124.09% |
-77.51% |
|
-120.46% |
|
$51.32 |
|
$-12.68 |
|
$-12.68 |
|